Exendin-4 Inhibits Hepatic Lipogenesis by Increasing β-Catenin Signaling
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
The aim of this study is to investigate whether the beneficial effect of exendin-4 on hepatic steatosis is mediated by β-catenin signaling. After the HepG2 human hepatoma cells were treated with PA for 24 hours, total triglycerides levels were increased in a dose-dependent manner, and the expression levels of perilipin family members were upregulated in cells treated with 400 μM PA. For our in vitro model of hepatic steatosis, HepG2 cells were treated with 400 μM palmitic acid (PA) in the presence or absence of 100 nM exendin-4 for 24 hours. PA increased the expression of lipogenic genes, such as sterol regulatory element-binding protein 1c (SREBP-1c), peroxisome proliferator-activated receptor gamma (PPARγ), stearoyl-CoA desaturase 1 (SCD1), fatty acid synthase (FAS), and acetyl-CoA carboxylase (ACC) and triglyceride synthesis-involved genes, such as diacylglycerol acyltransferase 1 (DGAT1) and diacylglycerol acyltransferase 2 (DGAT2) in HepG2 cells, whereas exendin-4 treatment significantly prevented the upregulation of SREBP-1c, PPARγ, SCD1, FAS, ACC, DGAT1 and DGAT2. Moreover, exendin-4 treatment increased the expression of phosphorylated glycogen synthase kinase-3 beta (GSK-3β) in the cytosolic fraction and the expression of β-catenin and transcription factor 4 (TCF4) in the nuclear fraction. In addition, siRNA-mediated inhibition of β-catenin upregulated the expression of lipogenic transcription factors. The protective effects of exendin-4 on intracellular triglyceride content and total triglyceride levels were not observed in cells treated with the β-catenin inhibitor IWR-1. These data suggest that exendin-4 treatment improves hepatic steatosis by inhibiting lipogenesis via activation of Wnt/β-catenin signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In this regard, liraglutide has been shown to reduce the hepatic expression of PPAR-γ and, consequently, the intrahepatocyte accumulation of fatty acids, restoring the physiological lipid homeostasis [122,123].”
From GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives (2023) · cites this paper as [123]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wnt/β-Catenin Signaling: Components, Mechanisms, and Diseases
MacDonald, B. T., Tamai, K., & He, X. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.06.016 · Cited by 5,583
The Wnt Signaling Pathway in Development and Disease
Logan, C. Y., & Nusse, R. (2004) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.20.010403.113126 · Cited by 5,325
Wnt signalling in stem cells and cancer
Reya, T., & Clevers, H. (2005) · Nature · doi:10.1038/nature03319 · Cited by 3,666
Variant of transcription factor 7-like 2 (TCF7L2) gene confers risk of type 2 diabetes
Grant, S. F. A., Thorleifsson, G., Reynisdottir, I., Benediktsson, R., Manolescu, A., Sainz, J., Helgason, A., Stefansson, H., Emilsson, V., Helgadottir, A., et al. (2006) · Nature Genetics · doi:10.1038/ng1732 · Cited by 2,287
Postic, C., & Girard, J. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34275 · Cited by 1,204
Neuschwander‐Tetri, B. A. (2010) · Hepatology · doi:10.1002/hep.23719 · Cited by 1,077
Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP‐1c
Ferré, P., & Foufelle, F. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01275.x · Cited by 704
Adipogenesis and WNT signalling
Christodoulides, C., Lagathu, C., Sethi, J. K., & Vidal-Puig, A. (2009) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2008.09.002 · Cited by 598
Ding, X., Saxena, N. K., Lin, S., Gupta, N., & Anania, F. A. (2006) · Hepatology · doi:10.1002/hep.21006 · Cited by 557
Gupta, N. A., Mells, J., Dunham, R. M., Grakoui, A., Handy, J., Saxena, N. K., & Anania, F. A. (2010) · Hepatology · doi:10.1002/hep.23569 · Cited by 532
Cited by
Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., & Sasso, F. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021703 · Cited by 286
“In this regard, liraglutide has been shown to reduce the hepatic expression of PPAR-γ and, consequently, the intrahepatocyte accumulation of fatty acids, restoring the physiological lipid homeostasis [122,123].”
BackgroundThe Heterogeneity of Lipid Metabolism in Cancer
Park, J. K., Coffey, N. J., Limoges, A., & Le, A. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-77736-8_3 · Cited by 82
Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis
Kalavalapalli, S., Bril, F., Guingab, J., Vergara, A., Garrett, T. J., Sunny, N. E., & Cusi, K. (2019) · Journal of Endocrinology · doi:10.1530/joe-19-0007 · Cited by 48
Khalifa, O., AL-Akl, N. S., Errafii, K., & Arredouani, A. (2022) · Scientific Reports · doi:10.1038/s41598-022-06143-5 · Cited by 42
The protective effects of Zhen-Wu-Tang against cisplatin-induced acute kidney injury in rats
Liu, Q., Shou-yu, H., He, Y., Zhang, J., Zeng, X., Gong, F., & Liang, L. (2017) · PLoS ONE · doi:10.1371/journal.pone.0179137 · Cited by 41
The Heterogeneity of Lipid Metabolism in Cancer
Park, J. K., Coffey, N. J., Limoges, A., & Le, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-65768-0_3 · Cited by 41
Inoue, T., Fu, B., Nishio, M., Tanaka, M., Kato, H., Tanaka, M., Itoh, M., Yamakage, H., Ochi, K., Ito, A., et al. (2023) · Nutrients · doi:10.3390/nu15020350 · Cited by 34
A Model of Hepatic Steatosis with Declined Viability and Function in a Liver-Organ-on-a-Chip
Wiriyakulsit, N., Keawsomnuk, P., Thongin, S., Ketsawatsomkron, P., & Muta, K. (2023) · Scientific Reports · doi:10.1038/s41598-023-44198-0 · Cited by 29
“HepG2 OOCs are likely less sensitive to PA exposure for inducing TAG synthesis than 2D HepG2 cultures in which PA increases TAG accumulation 33–35 .”
Ma, J., Feng, J.-F., & Zhou, X. D. (2020) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2020.104466 · Cited by 28
Gao, Z., Song, G., Ren, L., Ma, H., Ma, B., & Chen, S. (2020) · European Journal of Histochemistry · doi:10.4081/ejh.2020.3160 · Cited by 23
Deng, B., Zhu, W., Duan, Y., Hu, Y., Chen, X., Song, S., Yi, Z., & Song, Y. (2019) · Molecular Medicine Reports · doi:10.3892/mmr.2019.10764 · Cited by 19
“C), which corresponds to previous study (46).”
Errafii, K., Khalifa, O., Al-Akl, N. S., & Arredouani, A. (2022) · Biomedicines · doi:10.3390/biomedicines10051020 · Cited by 17
“Interestingly, in an in vitro cell model of steatosis, similar to the one we used in this study, Seo and colleagues [41] recently showed that Ex-4 treatment significantly reduced the expression of both PPARγ and SREBP-1c.”
Central administration of coagonist of GLP-1 and glucagon receptors improves dyslipidemia
PATEL, V. G., Joharapurkar, A. A., Kshirsagar, S. G., Sutariya, B., Patel, M. S., Patel, H., Pandey, D., Patel, D. N., Bahekar, R. H., & Jain, M. R. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.12.068 · Cited by 18
Exendin-4 protects mice from D-galactose-induced hepatic and pancreatic dysfunction
Ahangarpour, A., Oroojan, A. A., & Badavi, M. (2017) · Pathobiology of Aging & Age-related Diseases · doi:10.1080/20010001.2017.1418593 · Cited by 17
“Further, exendin-4 attenuates hepatic lipogenesis via ß-catenin activation [6].”
BackgroundIntestinal L-cell mechanoreception regulates hepatic lipid metabolism through GLP-1
Gao, L., Yang, K., Zhao, Y., Zhang, J., Jiang, S., Zhang, R., He, W., Zhao, Y., Ye, Q., & Xu, G. (2025) · Science Advances · doi:10.1126/sciadv.adv3201 · Cited by 14
“In HepG2, Huh7, and AML12 cells, the mRNA expression of β - catenin was found to increase in a dose-dependent and time-dependent manner following treatment with EX-4 ( 47 ).”
Yoo, J. H., Cho, I.-J., Jeong, I., Ahn, K. J., Chung, H. Y., & Hwang, Y. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.09.032 · Cited by 12
“EX-4 has been shown to alleviate hepatic fat accumulation via modulation of lipid metabolism both in vivo and in vitro (Ding et al., 2006; Seo et al., 2016).”
BackgroundErrafii, K., Al-Akl, N. S., Khalifa, O., & Arredouani, A. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-021-02885-4 · Cited by 12
“Emerging evidence indicates that GLP-1RAs can markedly reduce hepatic steatosis in vitro by modulating the expression of genes involved in lipid metabolism (inhibiting fatty acid synthesis-related genes and enhancing the expression of fatty acid oxidation-related genes) [16].”
BackgroundZhou, H., Zhu, X., Yao, Y., Su, Y., Xie, J., Zhu, M., He, C., Ding, J., Xu, Y., Shan, R., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.798735 · Cited by 14
“According to relevant experimental reports, the Wnt/β-catenin signaling pathway can regulate liver lipid anabolism by regulating other regulatory cytokines, such as SREBP-1c, FAS, and PPAR family (Xu et al., 2014; Seo et al., 2016).”
BackgroundLee, J., Hong, S., Kwon, H., Park, S. E., Rhee, E., Park, C., Oh, K.-W., Park, S. W., & Lee, W. (2018) · Cell Stress and Chaperones · doi:10.1007/s12192-017-0872-z · Cited by 12
Self-citationAlcohol-Associated Hepatocarcinogenesis
Xue, Y., Tian, T., Ottallah, M., Mannan, M., Barkin, J., Jin-Smith, B., & Pi, L. (2025) · American Journal Of Pathology · doi:10.1016/j.ajpath.2025.04.016 · Cited by 11
“15 Activation of the Wnt/ b -catenin pathway d especially through GSK 3 b inhibition d up-regulates PPAR a , 16 enhancing fatty acid oxidation and promoting lipid clearance.”
Kim, N., Jung, S., Lee, E. J., Jo, E.-B., Yoon, S., & Jeong, Y. (2022) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2022.115117 · Cited by 11
Khalifa, O., Mroué, K. H., Mall, R., Ullah, E., Al-Akl, N. S., & Arredouani, A. (2022) · Biomedicines · doi:10.3390/biomedicines10102652 · Cited by 10
Lim, D., Kim, H., Lee, S.-J., Yu, G., Kim, J., & Park, W. (2019) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2019/4589810 · Cited by 11
“It has been established that CPT-1 facilitates fatty acid transportation into mitochondria and, thus, promotes beta-oxidation [33], and C/EBPα and PPARγ are essential transcription factors that participate in lipogenesis and increase hepatic triglyceride levels [34, 35], which we found were significantly modulated by…”
BackgroundLi, B., Fan, H., Wu, H., Zhang, Y., Ding, N., Liu, P., Wang, Q., Cao, M., Meng, Z., Feng, X., et al. (2025) · Blood · doi:10.1182/blood.2024027772 · Cited by 11
Salt‐inducible kinase 2 functions as a tumor suppressor in hepatocellular carcinoma
Yuan, L., Yu, J., Jia, M., Ma, P., & Dong, C. (2021) · Environmental Toxicology · doi:10.1002/tox.23366 · Cited by 9
“Seo et al found that Exendin-4 improved hepatic steatosis by inhibiting hepatic lipogenesis by activation of the Wnt/β-catenin signaling.(38) A recent study suggested that SIK2 suppressed the protein kinase B/glycogen synthase kinase 3β/β-catenin signaling and acted as a tumor suppressor in gastric cancer.”
BackgroundExendin-4 as a Versatile Therapeutic Agent for the Amelioration of Diabetic Changes
Rajabi, H., Ahmadi, M., Aslani, S., Saberianpour, S., & Rahbarghazi, R. (2021) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2022.025 · Cited by 11
“9 | P a g e SREBP-1.(101) The use of Ex-4 in steatoric patients remove excessive fatty acids via regulating lipid metabolism and reducing VLDL synthesis after suppression of genes such as peroxisome Pgc1β, transcription factor Srebp-1c and Fasn, Dgat1, and Apob.”
BackgroundZhou, S., Obianom, O. N., Huang, J., Guo, D., Yang, H., Li, Q., & Shu, Y. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13030330 · Cited by 7
RetractedKhalifa, O., & Arredouani, A. (2026) · Pharmaceuticals · doi:10.3390/ph19030408 · Cited by 8
“Steatosis is typically induced using palmitic acid (PA), which triggers lipotoxicity, ER stress, and inflammation [51] or oleic acid (OA), which promotes lipid deposition with comparatively lower inflammatory signaling [52–54].”
Sun, J., Jin, X., & Li, Y. (2024) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2024.167555 · Cited by 7
RSPO1, a potent inducer of pancreatic β cell neogenesis
Silvano, S., Napolitano, T., Plaisant, M., de Veiga, A. S., Fofo, H., Ayachi, C., Allegrini, B., Rekima, S., Pichery, E., Becam, J., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102126 · Cited by 9
Khalifa, O., Ouararhni, K., Errafii, K., Alajez, N. M., & Arredouani, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411606 · Cited by 8
“Quantification of Steatosis As described in our previous studies, the steatosis was quantified by triglyceride measurement [18,66] using a commercial fluorometric test kit (Abcam TG Quantification Assay Kit, ab65336) and a microplate reader to detect total TGs levels (Infinite F200 Pro; Tecan, Männedorf, Switzerland).”
BackgroundMethodKhalifa, O., Ayoub, S., & Arredouani, A. (2025) · Biomedicines · doi:10.3390/biomedicines13020370 · Cited by 4
“Noteworthy, we [21] and others [22] previously showed that Ex-4-induced improvement of OA-induced steatosis in HepG2 implicates the Wnt/ β -catenin pathway.”
Zhang, Y., Wang, H., Wang, F., Guo, X., Zhao, M., Zhou, Z., Lin, X., Zheng, L., Wang, Y., Liu, C., et al. (2025) · Clinical Science · doi:10.1042/cs20257764 · Cited by 2
“We used 400 μmol PA, a concentration frequently used to study hepatic lipogenesis as previously reported [32], to stimulate HepG2 cells with or without FC.”
Wu, L., Liang, Z., Yang, Z., Wang, H., Ni, L., Guo, W., & Lv, X. (2025) · eFood · doi:10.1002/efd2.70048 · Cited by 1
Effect of Incretogenic Peptides on Non-Alcoholic Fatty Liver Disease
苏, 怡. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.1361396
정도원 (2024) · Seoul National University Open Repository (Seoul National University)
Cross, E., Westcott, F., Smith, K. H., Nagarajan, S. R., Sanna, F., Dennis, K. M. J. H., & Hodson, L. (2026) · Physiological Reports · doi:10.14814/phy2.70989
Fan, L., Chen, C., Li, X., Yang, R., Wang, H., & Shi, H. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.6c00383
Metadata
- Authors
- Seo, M. H., Lee, J., Hong, S.-W., Rhee, E.-J., Park, S. E., Park, C. Y., Oh, K. W., Park, S. W., & Lee, W.-Y.
- Affiliations
- Soonchunhyang University (KR)
- Kangbuk Samsung Hospital (KR)
- Corresponding author
- Lee, Won-Young
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-12-01
- Volume
- 11
- Issue
- 12
- Pages
- e0166913
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC5131969
- OpenAlex
- W2557879692
- Cited by
- 37
- References
- 31
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 1 · 2023: 5 · 2022: 5 · 2021: 5 · 2020: 2 · 2019: 3 · 2018: 3 · 2017: 3
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Funders
- National Research Foundation of Korea (KR) (NRF-2013R1A1A2063069)
- Samsung Biomedical Research Institute
- Topics
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Wnt/β-catenin signaling in development and cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Keywords
- exendin-4, hepatic steatosis, hepatic lipogenesis, Wnt/β-catenin signaling, glycogen synthase kinase-3β, SREBP-1c, PPARγ, stearoyl-CoA desaturase 1, fatty acid synthase, acetyl-CoA carboxylase, diacylglycerol acyltransferase, triglyceride synthesis, palmitic acid, hepatocytes, IWR-1
- MeSH terms
- Glycogen Synthase Kinase 3 beta, Transcription Factor 4, Exenatide, Acetyl-CoA Carboxylase, Cell Nucleus, Cytosol, Gene Expression Regulation, Humans, Hypoglycemic Agents, Imides, Peptides, Quinolines, Stearoyl-CoA Desaturase, Transcription Factors, Venoms, Palmitic Acid, RNA, Small Interfering, PPAR gamma, Lipogenesis, Diacylglycerol O-Acyltransferase, beta Catenin, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Sterol Regulatory Element Binding Protein 1, Fatty Acid Synthase, Type I, Hep G2 Cells, Wnt Signaling Pathway
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.